FDA Has No Major Concerns With Lilly Alzheimer's Drug
Favicon 
www.newsmax.com

FDA Has No Major Concerns With Lilly Alzheimer's Drug

An FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease. The drug is a potential rival to Eisai and Biogen's...